tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Siekierka JJ et al. | Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. | 1991 | Transplant. Proc. | pmid:1721256 |
| Morris RE | In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. | 1991 | Transplant. Proc. | pmid:1721257 |
| Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
| Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
| Loréal O et al. | FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. | 1991 | Transplant. Proc. | pmid:1721289 |
| McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
| McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
| Chen-Woan M et al. | Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721320 |
| Fukuzawa M et al. | Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. | 1991 | Transplant. Proc. | pmid:1721321 |
| Takaori K et al. | Effects of FK 506 on in vivo immunity in comparison to cyclosporine. | 1991 | Transplant. Proc. | pmid:1721322 |
| Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
| Green M et al. | Infectious complications of pediatric liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721352 |
| Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
| Torre-Cisneros J et al. | The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721353 |
| Starzl TE et al. | Hepatotrophic effects of FK506 in dogs. | 1991 | Transplantation | pmid:1702912 |
| Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
| Keicho N et al. | Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. | 1991 | Cell. Immunol. | pmid:1703047 |
| Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
| White DJ | FK506: the promise and the paradox. | 1991 | Clin. Exp. Immunol. | pmid:1703053 |
| McCauley J et al. | Changes in renal function after liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721385 |
| Tauxe WN et al. | A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. | 1991 | Transplant. Proc. | pmid:1721386 |
| McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
| Hossein-Nia M et al. | Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721388 |
| Fukuzaki T et al. | Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. | 1991 | Transplant. Proc. | pmid:1721415 |
| Tzakis AG et al. | FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721416 |
| Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
| Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| Fabrega AJ et al. | FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1721447 |
| Davies CB et al. | Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. | 1991 | Transplant. Proc. | pmid:1721448 |
| Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
| Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Ochiai T et al. | [Immunosuppressive agents--advances of the developmental studies and the mode of action]. | 1991 | Nippon Rinsho | pmid:1715926 |
| Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |
| Katz IA et al. | Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. | 1991 | Transplantation | pmid:1716801 |
| Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
| Pezze JL and Whiteman K | Transplantation's newest weapon FK 506. | 1991 | Am J Nurs | pmid:1716857 |
| Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
| Marquis-Omer D et al. | Stabilization of the FK506 binding protein by ligand binding. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1716886 |
| Jamieson NV et al. | Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. | 1991 | Clin Transpl | pmid:1726459 |
| Takahara S et al. | Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. | 1991 | J Clin Lab Immunol | pmid:1726566 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |